CVS Health (NYSE:CVS) Given New $108.00 Price Target at Truist Financial

CVS Health (NYSE:CVS) had its target price boosted by stock analysts at Truist Financial from $102.00 to $108.00 in a research note issued on Monday, MarketBeat.com reports. The firm presently has a “buy” rating on the pharmacy operator’s stock. Truist Financial’s price objective points to a potential upside of 19.05% from the stock’s current price.

CVS has been the topic of a number of other reports. Weiss Ratings reissued a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. Argus lifted their price target on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. Mizuho increased their target price on shares of CVS Health from $102.00 to $110.00 and gave the stock an “outperform” rating in a report on Wednesday, May 20th. Wolfe Research decreased their price objective on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Finally, The Goldman Sachs Group upped their target price on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.68.

CVS Health Trading Down 0.3%

CVS traded down $0.26 during trading on Monday, reaching $90.72. 255,463 shares of the company’s stock were exchanged, compared to its average volume of 8,503,558. The company’s fifty day moving average price is $82.07 and its 200-day moving average price is $79.56. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market capitalization of $115.75 billion, a PE ratio of 39.86, a P/E/G ratio of 0.89 and a beta of 0.62. CVS Health has a fifty-two week low of $58.50 and a fifty-two week high of $98.43.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the company earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts forecast that CVS Health will post 7.44 EPS for the current year.

Insider Transactions at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last quarter. Corporate insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On CVS Health

A number of institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd increased its stake in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares in the last quarter. Swiss RE Ltd. acquired a new stake in CVS Health in the fourth quarter worth $26,000. Sankala Group LLC bought a new stake in CVS Health in the fourth quarter valued at $28,000. Global Trust Asset Management LLC raised its holdings in shares of CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health during the 4th quarter worth about $28,000. 80.66% of the stock is currently owned by institutional investors.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.